The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

By Y. Park, Shankuan Zhu, L. Palaniappan, S. Heshka, M. Carnethon, Steven B. Heymsfield. Archives of Internal Medicine, 2003

2,333 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/41bc803f2e32b9222bc2d7ef2ccc3b2fa5e66e74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

Citations in the corpus

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “While certain racial/ethnic features that increase the risk of diabetes are well recognised (greater insulin resistance in Latinos [107], more beta cell dysfunction in East Asians [108]), using this information to craft optimal therapeutic strategies is in its infancy.”
Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. (2005, neutral): “In the United States, 35–42% of white men and women who are 65 y of age and who have the metabolic syndrome have low HDL-cholesterol ( 40 mg/dL in men and 50 mg/dL in women) and high triacylglycerol ( 150 mg/dL) concentrations (51).”
Metabolic syndrome update. (2016, background): “[10] Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB.”
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis (2015, result): “Consistent with population studies (33,34), we found no significant difference between men and women.”
A Comprehensive Review on Metabolic Syndrome (2014, background): “…(WHO) [5], the European Group for the study of Insulin Resistance (EGIR) [6], the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) [7], American Association of Clinical Endocrinologists (AACE) [8], and the International Diabetes Federation (IDF) [9] (Table 1).”
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. (2005, methodology): “0%); however, African American and Hispanic women were notable exceptions, with prevalences 57% and 26% greater, respectively than their male counterparts (Park et al., 2003).”